Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins

AIDS

Volumn 20, Issue 17, 2006, Pages 2159-2164

  Negredo, Eugenia ^a,b   Moltó, José ^a   Puig, Jordi ^a   Cinquegrana, Denise ^a   Bonjoch, Anna ^a   Pérez Álvarez, Núria ^a   López Blázquez, Raquel ^a   Blanco, Asunción ^a   Clotet, Bonaventura ^a   Rey Joly, Celestino ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Antiretroviral therapy; Dyslipidaemia; Ezetimibe; HIV infection; Pharmacokinetic interactions; Statins

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; APOPROTEIN; C REACTIVE PROTEIN; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; MYOPATHY; PRIORITY JOURNAL; SKELETAL MUSCLE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AZETIDINES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33750587038     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000247573.95880.db     Document Type: Article

References (23)

1. Masana L, Mata P, Gagne C, Sirah W, Cho M, Johnson-Levonas AO, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther 2005; 27:174-184.
2. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90:1084-1091.
3. Gagne C, Gaudet D, Bruckert E, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hyper cholesterolemia. Circulation 2002; 105:2469-2475.
4. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91:418-424.
5. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80:585-586.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper D. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
7. Friis-Møller N, Reiss P, El-Sadr W, D'Arminio A, Monfort R, Thiébaut S, et al. Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D Study.Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 144].
8. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17:S141-S148.
9. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577.
10. Calza L, Manfredi R, Chiodo F. Statins and fibrate for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17:851-859.
11. Reyderman L, Kosoglou T, Cutler DL, Maxwell S, Statkevich P. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Curr Med Res Opin 2005; 21:1171-1179.
12. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44:467-494.
13. Droste JAH, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32:287-291.
14. Lichtenstein K, Armon C, Buchacz K, Moorman A, Wood K, Brooks J, et al. Analysis of cardiovascular risk factors in the HIV Outpatient Study Cohort. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 735].
15. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2529-2531.
16. Friis-Moller N, Sabin CA, Weber R, d'Armonio Monforte A, El-Sadr WM, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
17. Bucher H, Glass T, Weber R. and the Swiss HIV Cohort Study. Predictors of successful blood pressure management in HIV-infected patients at moderate to high 10-year risk of coronary heart disease: The Swiss HIV Cohort Study. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 740].
18. Negredo E, Ribalta J, Paredes R, Ferré R, Sirera G, Ruiz L, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16:1383-1389.
19. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. New Engl J Med 2003; 349:1036-1046.
20. Raffi F, Bonnet B, Ferre V, Esnault JL, Perre P, Reliquet V, et al. Substitution of a Nonnucleoside Reverse transcriptase inhibitor for a Protease Inhibitor in the treatment of Patient with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000; 31:1274-1278.
21. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, et al. Efficacy and safety of Atazanavir (ATV) based HAART in patients switched from a stable boosted/unboosted protease inhibitor (PI) treatment. The Swan study. Tenth European AIDS Society/ EACS. Dublin, Ireland, November 2005 [abstract PS1/1].
22. McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 2005; 96:60E-66E.
23. Plosch T, Kosters A, Groen AK, Kuipers F. The ABC of hepatic and intestinal cholesterol transport. Handb Exp Pharmacol 2005; 170:465-482.